Language
Country/Area
No result found
Innovator in cancer research: How Ugur Sahin became a leader in immunology
As the world confronts the COVID-19 pandemic, Uğur Şahin, co-founder and CEO of biotech company BioNTech, has quickly become a key figure in shortening vaccine development time. His research expertise spans cancer research and immunology, and his impact on the future biomedical community cannot be ignored. From an ordinary son of Turkish immigrants to becoming one of the world's top scientists, Shaheen's success story is full of breakthroughs and innovations.
"My mission is to harness our body's immune system to fight cancer."
Early life and education
Ugur Shaheen was born in Iskenderun, Turkey, on September 19, 1965. When he was four, his mother moved to Germany to reunite with his father, who worked at the Cologne Automobile Factory. He grew up in Cologne, where the education system was not always friendly to children of immigrants, and his teachers initially recommended that he attend a lower school. However, with the help of his German neighbors, he enrolled in a strong sports school, excelled academically, and eventually graduated in 1984. Shaheen studied medicine at the University of Cologne from 1984 to 1992 and received his PhD in the field of immunotherapy.
The beginning of your career
Shahin began his career in the Department of Internal Medicine and Oncology at the University Hospital Cologne, where he worked from 1991 to 2000, and later as a physician at the University Hospital Saarland. During this period he conducted a number of important studies focusing on molecular medicine and immunology. In 2000 he founded a research group at the University of Mainz and since 2001 has accumulated extensive academic experience as Professor of Experimental Oncology.
"I am never satisfied with the status quo. My goal is to create new treatments to solve difficult problems in medicine."
The establishment of BioNTech and its impact
In 2008, Shaheen co-founded BioNTech with his wife and partners. The company is focused on developing personalized cancer immunotherapies and conducting in-depth research on mRNA technology. BioNTech has risen rapidly in the development of COVID-19 vaccines and has partnered with US-based Pfizer to develop the BNT162b2 vaccine, which became the world's first approved mRNA vaccine.
Scientific research achievements and awards
As a medical scientist, Shaheen has published more than 345 studies and received awards at various medical conferences. He has created new research areas in the development of personalized medicine and cancer immunotherapy. It is particularly worth mentioning that Shaheen and his team have made great progress in the research of tumor antigens and pioneered an mRNA vaccine based on a patient's own tumor mutations. This technology has the potential to fundamentally change the landscape of cancer treatment.
"Our goal is to provide a vaccine tailored to each patient's tumor mutations."
Vision for the future
Shahin’s research and innovation is not limited to cancer vaccines but also extends to treatments for other autoimmune diseases. He believes that advances in technology can defeat cancer in the future and is actively promoting clinical trials of new treatments. For Shaheen, this is not a personal battle, but a battle about human survival, and every step of progress may bring changes to the future.
With the rapid development of global medical technology, Shaheen's story has inspired countless people to get in touch with science and pursue medical excellence. Where will cancer treatment go in the future?
